Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients With Psychogenic Nonepileptic Seizures

NCT ID: NCT06647056

Last Updated: 2025-08-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 4 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-12-19
• Study Completion Date: 2025-05-22

Brief Summary

Psychogenic non-epileptic seizures (PNES) are functional paroxysmal motor disorders that may be clinically suggestive of epilepsy but are not associated with the electroencephysiological and electroencephalographic changes of epilepsy. Thus, hyper-connectivity of the regions of the default mode network (DMN) linked to executive control could be involved in the impairment of cognitive control capacities in patients suffering from PNES. Also, the HYCORE study (NCT02329626), showed that dysregulation of frontal regions involved in attentional and emotional regulation is correlated with motor symptoms in patients with functional neurological disorders.

The researchers of this study hypothesized that psilocybin would improve cognitive control in patients with PNES.

Conditions

Psychogenic Nonepileptic Seizures; Psilocybin

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Patients with PNES

Group Type: EXPERIMENTAL

Psilocybin

Intervention Type: DRUG

Administration of psilocybin 25 mg

MRI

Intervention Type: OTHER

Two standard MRI + fMRI scans before (D-3) and after (D5) treatment

Interventions

Psilocybin

Administration of psilocybin 25 mg

Intervention Type: DRUG

MRI

Two standard MRI + fMRI scans before (D-3) and after (D5) treatment

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Euthymic patient according to the MINI questionnaire.
• Diagnosis of PNES confirmed by video-EEG, progressing for more than 3 months, and meeting DSM5 criteria.
• Normal brain MRI during the assessment as part of routine care
• No contraindication to stopping any antidepressant treatment for a fortnight (or 5 weeks for fluoxetine) prior to the administration of psilocybin. Other psychotropic treatments will not be interrupted.
• Patient must have given their free and informed consent and signed the consent form
• Patient must be a member of beneficiary of a health insurance plan
• Patient available for a total of 6 months follow-up.
• Good physical health and absence of unstable medical pathology. These pathologies include cardiovascular co-morbidities: history of stroke, myocardial infarction, heart failure, arrhythmia, uncontrolled hypertension (greater than 165/95 mmHg at screening); organic epileptic syndrome and active neurological comorbidities; endocrine pathologies (dysthyroid and adrenal insufficiency, type 1 diabetes or insulin-requiring type II diabetes, history of severe hypoglycaemia requiring hospital treatment); considerable impairment of liver function; glaucoma; symptomatic prostatic hypertrophy or bladder neck obstruction.
• Ability to understand and speak French

Exclusion Criteria

• Serious risk of suicide according to the clinician opinion.
• High risk of adverse emotional or behavioural reaction as clinically assessed by the investigator (e.g. severe personality disorder, antisocial behaviour, severe current stress factors, lack of consequent social support).
• Active dependence on a substance according to the MINI questionnaire (excluding tobacco).
• Psychotropic treatment (anxiolytics, antipsychotics, hypnotics) modified in the last month.
• Patient with intellectual disability.
• A lifetime history of bipolar disorder, schizophrenia, schizoaffective disorder or psychosis not otherwise specified.
• Family history of schizophrenia, schizoaffective disorder or type 1 bipolar disorder in first or second degree relatives.
• Any unstable disease or physical condition determined by history or laboratory tests (ECG, blood tests at inclusion). These conditions include cardiovascular co-morbidities: history of stroke, myocardial infarction, heart failure, arrythmia, uncontrolled hypertension (greater than 165/95 mmHg at screening); organic epileptic syndrome and active neurological comorbidities; endocrine pathologies (dysthyroid and adrenal disorders, type I diabetes or insulin-requiring type II diabetes, history of severe hypoglycaemia requiring hospital treatment); considerable impairment of liver function; glaucoma, symptomatic prostatic hypertrophy or bladder neck obstruction.
• Presence of neurological comorbidities.
• Medical conditions that would preclude safe participation in the trial; for example: considerable impairment of liver function, coronary artery disease, history of arrythmia, heart failure, uncontrolled hypertension (greater than 165/95 mmHg at screening). History of stroke, severe asthma, hyperthyroid, narrow angle glaucoma, uncontrolled type I or type II diabetes or history of ketoacidosis, hyperglycaemic coma or severe hypoglycaemia with loss of consciousness.
• Participants planning to donate sperm within three months of psilocybin administration.
• Participants having sexual intercourse that could lead to pregnancy and who do not agree to use a highly effective contraceptive method (contraceptive ring, surgical contraception, implant, patch, contraceptive pill, male and female condoms, IUD) throughout their participation in the study and for at least three months after administration of psilocybin.
• Positive serum pregnancy test at inclusion for participants of childbearing age NB: serum pregnancy test will be performed prior to administration of psilocybin.
• Contraindications to magnetic resonance imaging.
• Allergy, hypersensitivity or other adverse reaction to previous use of psilocybin or other hallucinogens.
• Consumption of hallucinogenic substances (excluding cannabis) more than 10 times in a lifetime or in the last 2 months, regardless of frequency.
• Use of medication likely to interfere with the effects of psychedelics.
• Regular consumption of alcoholic beverages (>20 drinks/week).
• Any other major clinically considerable concomitant disease which, in the opinion of the investigator, may interfere with the interpretation of the results of the study or constitute a risk to the health of the participant, should they take part in the study.
• Patient with a prolonged QTc interval (interval >450 ms for men and >470 ms for women)
• Patient taking part in an interventional drug study.
• Patient in a period of exclusion determined by another study.
• Patient under court protection, guardianship or curatorship.
• Patient unable to give consent.
• Patient to whom it is impossible to communicate informed information
• Patient with a positive pregnancy test prior to psilocybin administration.
• Any patient who has been hospitalised on an outpatient or inpatient basis between the date of inclusion and the administration of psilocybin.
• Any patient who has made a known, interrupted or aborted suicide attempt between the date of inclusion and the administration of psilocybin.
• Any patient who has expressed suicidal ideation associated with the planning of a suicidal act (active suicidal ideation) between the date of inclusion and the administration of psilocybin.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Centre Hospitalier Universitaire de Nīmes

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ismaël CONEJERO

Role: PRINCIPAL_INVESTIGATOR

CHU Nimes

Locations

CHU de Nîmes, Hôpital Universitaire Carémeau

Nîmes, , France

Countries

France

Other Identifiers

NIMAO/2022-2/IC01

Identifier Type: -

Identifier Source: org_study_id